Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours.
As for any solid tumour, pituitary adenoma expansion is dependent on neovascularization through angiogenesis. In this process, vascular endothelial growth factor (VEGF) and its receptors VEGFR-1, VEGFR-2 and neuropilin-1 (NRP-1) may play an outstanding role. The intention of this work was to study the expression/localization and possible function of VEGF receptors in pituitary adenomas. VEGF receptor mRNA and protein expression was studied by in situ hybridization, immunohistochemistry and RT-PCR in 6 normal human pituitaries, 39 human pituitary adenomas and 4 rodent pituitary adenoma cell lines. VEGFR-1 expressing somatotroph MtT-S cells were used as a model to study the role of VEGF on cell proliferation and to elucidate the underlying mechanism of action. In normal pituitaries, VEGFR-1 was detected in endocrine cells, whereas VEGFR-2 and NRP-1 were exclusively expressed in endothelial cells. In pituitary tumours, a heterogeneous VEGFR expression pattern was observed by IHC. VEGFR-1, VEGFR-2 and NRP-1 were detected in 24, 18 and 17 adenomas respectively. In the adenomas, VEGFR-1 was expressed in epithelial tumour cells and VEGFR-2/NRP-1 in vessel endothelial cells. Functional studies in VEGFR-1-positive MtT-S cells showed that the ligands of VEGFR-1 significantly stimulated cell proliferation. This effect was mediated through the phosphatidylinositol-3-kinase-signalling pathway and involves induction of cyclin D1 and Bcl-2. Based on our results, we speculate that the ligands of VEGF receptors, such as VEGF-A and placenta growth factor, not only play a role in angiogenesis in pituitary adenomas, but also affect the growth of pituitary tumour cells through VEGFR-1.
Onofri
Chiara
C
Max-Planck-Institute of Psychiatry, Neuroendocrinology Group, Kraepelinstr. 10, D-80804 Munich, Germany. onofri@mpipsykl.mpg.de
Theodoropoulou
Marily
M
Losa
Marco
M
Uhl
Eberhard
E
Lange
Manfred
M
Arzt
Eduardo
E
Stalla
Günter K
GK
Renner
Ulrich
U
D000236:Adenoma / Q000737:chemistry* / Q000378:metabolism / Q000473:pathology; D000328:Adult; D000368:Aged; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D015153:Blotting, Western / Q000379:methods; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002867:Chromones / Q000494:pharmacology; D042783:Endothelial Cells / Q000737:chemistry; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D017403:In Situ Hybridization / Q000379:methods; D008024:Ligands; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000494:pharmacology; D039942:Neuropilin-1 / Q000235:genetics; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010902:Pituitary Gland / Q000737:chemistry* / Q000378:metabolism; D010911:Pituitary Neoplasms / Q000737:chemistry* / Q000378:metabolism / Q000473:pathology; D051381:Rats; D040262:Receptors, Vascular Endothelial Growth Factor / Q000032:analysis* / Q000276:immunology / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D052683:Somatotrophs / Q000166:cytology / Q000187:drug effects; D013268:Stimulation, Chemical; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis / Q000378:metabolism* / Q000494:pharmacology; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000032:analysis / Q000235:genetics; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000032:analysis / Q000235:genetics
D000911:Antibodies, Monoclonal; D002867:Chromones; D008024:Ligands; D009025:Morpholines; D000081082:Phosphoinositide-3 Kinase Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D039942:Neuropilin-1; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; D040262:Receptors, Vascular Endothelial Growth Factor; D040281:Vascular Endothelial Growth Factor Receptor-1; D040301:Vascular Endothelial Growth Factor Receptor-2